Chorea is a characteristic type of involuntary movement in Huntington’s disease. This movement is often described as a smooth, writhing, squirmy, or twisting motion. It can affect any part of ...

A new drug was approved for Huntington's chorea in 2023, and novel insights about Huntington's disease emerged in new research. Valbenazine for Huntington's Chorea In August, the FDA expanded the ...

The Huntington disease (HD) Digital Motor Score (HDDMS), which is derived from smartphone sensor-based motor tests included ...

The drug valbenazine statistically improves chorea, a movement disorder commonly associated with Huntington's disease, when compared to a placebo. The drug valbenazine statistically improves ...

Huntington’s disease is a rare and incurable hereditary ... HD, also known as Huntington’s chorea, leads to symptoms that may impact movement, behavior, and cognition. According to the Genetic ...

"Huntington's disease has long been considered a disease ... as well as medical management of chorea. How functional, cognitive, and motor scores varied over time was also assessed.

Too much of dopamine can cause problems.‌ The most widely recognized cause of chorea is Huntington's disease — a hereditary disorder. But, there can be many other causes, some of which are ...

Credit: Neurocrine Biosciences. Nearly half of patients receiving Ingrezza saw a more than 40% reduction in Huntington disease chorea severity by the end of the treatment period. The Food and Drug ...

Yes, in fact, on August 18th, 2023, the FDA approved Valbenazine, or INGREZZA, for the treatment of chorea in adults with Huntington’s disease. The FDA’s decision was based on data from the ...

Recently, Neurocrine submitted a proposal to the FDA for the use of Ingrezza (valbenazine) as a treatment for chorea associated with Huntington's disease. The decision from the FDA is expected to ...

The Huntington’s disease treatment market is evolving, with novel therapies targeting mHTT and reshaping the future of ...

The current interim results from KINECT-HD2 (Sustained Improvements With Once-Daily Valbenazine in Chorea Associated With Huntington's Disease: Interim Results From a Long-Term Open-Label Study ...